Transcriptional deficits in oxidative phosphorylation with statin myopathy

Introduction: Hydroxymethylglutaryl–coenzyme A (HMG‐CoA) reductase inhibitors, or statins, are widely used drugs for hyperlipidemia and are generally well‐tolerated, but the can produce skeletal muscle toxicity. The molecular mechanisms driving statin myopathy are unknown. We investigated the effects of statin treatment and eccentric (damaging) exercise on transcriptional patterns between statin myopathy (Sym; N = 9) and statin‐tolerant subjects (Asym; N = 6). Methods: Skeletal muscle biopsies were collected 6 h post‐exercise at baseline and after statin treatment. Subjects performed concentric (non‐damaging) exercise with one leg and concentric + eccentric exercise with the other leg using a cross‐over design between time‐points. Results: Sym as compared with Asym demonstrated decreased skeletal muscle gene expression for oxidative phosphorylation–related and mitochondrial ribosomal protein genes before and after statin treatment with eccentric exercise. Conclusions: These results suggest that pre‐existing deficiencies in energy production may contribute to the development of symptoms during statin therapy, especially when muscle is exposed to eccentric exercise. Muscle Nerve 44: 393–401, 2011

[1]  F. Westwood,et al.  Blunted Akt/FOXO signalling and activation of genes controlling atrophy and fuel use in statin myopathy , 2009, The Journal of physiology.

[2]  S. Heales,et al.  Decreased Ubiquinone Availability and Impaired Mitochondrial Cytochrome Oxidase Activity Associated With Statin Treatment , 2009, Toxicology mechanisms and methods.

[3]  H. Jacobs,et al.  Modulation of Mrps12/Sarsm promoter activity in response to mitochondrial stress. , 2008, Biochimica et biophysica acta.

[4]  M. Tarnopolsky,et al.  Gene expression profiling in human skeletal muscle during recovery from eccentric exercise. , 2008, American journal of physiology. Regulatory, integrative and comparative physiology.

[5]  Michiaki Yamashita,et al.  The muscle-specific ubiquitin ligase atrogin-1/MAFbx mediates statin-induced muscle toxicity. , 2007, The Journal of clinical investigation.

[6]  L. Brewster,et al.  Distribution of creatine kinase in the general population: implications for statin therapy. , 2007, American heart journal.

[7]  R. Capaldi,et al.  Mitochondrial impairment by PPAR agonists and statins identified via immunocaptured OXPHOS complex activities and respiration. , 2007, Toxicology and applied pharmacology.

[8]  P. Thompson,et al.  Statin myopathy: Incidence, risk factors, and pathophysiology , 2007, Current atherosclerosis reports.

[9]  P. Thompson,et al.  Statins Provoking MELAS Syndrome , 2007, European Neurology.

[10]  P. Thompson,et al.  Statins provoking MELAS syndrome. A case report. , 2007, European neurology.

[11]  A. Dirks,et al.  Statin-induced apoptosis and skeletal myopathy. , 2006, American journal of physiology. Cell physiology.

[12]  P. Thompson,et al.  Analysis of human skeletal muscle after 48 h immobilization reveals alterations in mRNA and protein for extracellular matrix components. , 2006, Journal of applied physiology.

[13]  Zachary Simmons,et al.  Genetic risk factors associated with lipid‐lowering drug‐induced myopathies , 2006, Muscle & nerve.

[14]  R. Laaksonen.  On the mechanisms of statin‐induced myopathy , 2006, Clinical pharmacology and therapeutics.

[15]  Harlan M Krumholz,et al.  Withdrawn: P68 , 2006 .

[16]  E. Bruckert,et al.  Mild to Moderate Muscular Symptoms with High-Dosage Statin Therapy in Hyperlipidemic Patients —The PRIMO Study , 2005, Cardiovascular Drugs and Therapy.

[17]  E. Hoffman,et al.  Changes in Ubiquitin Proteasome Pathway Gene Expression in Skeletal Muscle With Exercise and Statins , 2005, Arteriosclerosis, thrombosis, and vascular biology.

[18]  P. Bénit,et al.  Succinate dehydrogenase deficiency in human , 2005, Cellular and Molecular Life Sciences CMLS.

[19]  T. Lehtimäki,et al.  High‐dose statins and skeletal muscle metabolism in humans: A randomized, controlled trial , 2005, Clinical pharmacology and therapeutics.

[20]  Okio Hino,et al.  A mutation in the SDHC gene of complex II increases oxidative stress, resulting in apoptosis and tumorigenesis. , 2005, Cancer research.

[21]  M. Sailer,et al.  Primary carnitine deficiency: adult onset lipid storage myopathy with a mild clinical course , 2004, Journal of Clinical Neuroscience.

[22]  Eric P Hoffman,et al.  Balancing muscle hypertrophy and atrophy , 2004, Nature Medicine.

[23]  H Sinzinger,et al.  Professional athletes suffering from familial hypercholesterolaemia rarely tolerate statin treatment because of muscular problems. , 2004, British journal of clinical pharmacology.

[24]  W. H. Schaefer,et al.  Evaluation of ubiquinone concentration and mitochondrial function relative to cerivastatin-induced skeletal myopathy in rats. , 2004, Toxicology and applied pharmacology.

[25]  H. Yoshioka,et al.  Changes in magnetic resonance images in human skeletal muscle after eccentric exercise , 2004, European Journal of Applied Physiology and Occupational Physiology.

[26]  L. Teichholz.  Statin-associated myopathy with normal creatine kinase levels. , 2003, Annals of internal medicine.

[27]  E. Hoffman,et al.  Gene profiling in spinal cord injury shows role of cell cycle in neuronal death , 2003, Annals of neurology.

[28]  J. Molina,et al.  Myoglobinuria and COX deficiency in a patient taking cerivastatin and gemfibrozil , 2003, Neurology.

[29]  S. Grundy,et al.  ACC/AHA/NHLBI Clinical Advisory on the Use and Safety of Statins. , 2002, Circulation.

[30]  I. Hamilton-Craig,et al.  Statin‐associated myopathy , 2001, The Medical journal of Australia.

[31]  M. Tarnopolsky,et al.  Statin myopathies: pathophysiologic and clinical perspectives. , 2001, Clinical and investigative medicine. Medecine clinique et experimentale.

[32]  M. Barbagallo,et al.  Effects of simvastatin and atorvastatin administration on insulin resistance and respiratory quotient in aged dyslipidemic non-insulin dependent diabetic patients. , 2000, Atherosclerosis.

[33]  J. Infante,et al.  Secondary carnitine deficiency and impaired docosahexaenoic (22:6n‐3) acid synthesis: a common denominator in the pathophysiology of diseases of oxidative phosphorylation and β‐oxidation , 2000, FEBS letters.

[34]  J. Toivonen,et al.  Expression of the Gene for Mitoribosomal Protein S12 Is Controlled in Human Cells at the Levels of Transcription, RNA Splicing, and Translation* , 1999, The Journal of Biological Chemistry.

[35]  P. Thompson,et al.  Lovastatin increases exercise-induced skeletal muscle injury. , 1997, Metabolism: clinical and experimental.

[36]  H. Reichmann,et al.  Single muscle fibre analyses in 2 brothers with succinate dehydrogenase deficiency. , 1994, European neurology.

[37]  R. E. Hall,et al.  Mitochondrial myopathy with succinate dehydrogenase and aconitase deficiency. Abnormalities of several iron-sulfur proteins. , 1993, The Journal of clinical investigation.

[38]  F. Nóbrega,et al.  BCS1, a novel gene required for the expression of functional Rieske iron‐sulfur protein in Saccharomyces cerevisiae. , 1992, The EMBO journal.

[39]  P. Clarkson,et al.  Adaptation to exercise-induced muscle damage. , 1987, Clinical science.

[40]  J. Mcleod,et al.  The creatine kinase reference interval An assessment of intra- and inter-individual variation , 1985, Journal of the Neurological Sciences.